Uterine Papillary Carcinoma Research Articles

The correlation between the expression of LncRNA-OVAAL and the recurrence and prognosis of uterine papillary serous carcinoma after operation

Objective To investigate the relationship between long non-coding ovarian adenocarcinoma amplified RNA (LncRNA-OVAAL) and tumor recurrence and prognosis in uterine papillary serous carcinoma (UPSC). Methods From May 2012 to November 2016, 32 patients with UPSC in our hospital were selected as observation group, and 30 patients with other benign diseases were selected as control group. Real-time polymerase chain reaction (PCR) was used to detect the expression of LncRNA-OVAAL in the enrolled patients. The receiver operating characteristic (ROC) curve was used to analyze the cutoff value of LncRNA-OVAAL. The relationship between LncRNA-OVAAL expression and clinicopathological features was analyzed. The cumulative survival rate was calculated and survival analysis was performed. The Cox risk regression model was used to analyze the single-factor and multi-factor analysis of prognosis and overall survival rate. Results The expression of LncRNA-OVAAL in patients with UPSC was elevated, which was related to age, vascular invasion, menopause, recurrence and preoperative serum human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) (P<0.05). High expression of LncRNA-OVAAL was a risk factor for postoperative recurrence and overall survival in patients with UPSC (P<0.05). Conclusions The high expression of LncRNA-OVAAL has a certain evaluation value for predicting postoperative recurrence and prognosis in patients with UPSC. Key words: RNA, long noncoding; Uterine papillary serous carcinoma; Neoplasm recurrence; Prognosis

Adjuvant paclitaxel and carboplatin chemotherapy interposed with radiotherapy in a “sandwich” protocol for uterine papillary serous carcinoma: a single institution experience and review of literature

Adjuvant paclitaxel and carboplatin chemotherapy interposed with radiotherapy in a “sandwich” protocol for uterine papillary serous carcinoma: a single institution experience and review of literature

Diagnostic value of hysteroscopy in patients with abnormal uterine bleeding

Objective To investigate the diagnostic value of hysteroscopy in patients with abnormal uterine bleeding. Methods The clinical data of 547 cases of abnormal uterine bleeding were analyzed retrospectively.The diagnostic curettage was conducted after hysteroscopy, the specimens were examined by histopathology, the detection result of hysteroscopy and histopathological were compared. Results The sensitivity of hysteroscopy in diagnosed abnormal uterine cavity lesions was 95.83% (161/168), the specificity was 97.63% (370/379), the false positive rate was 2.37% (9/379), the false negative rate was 4.17% (7/168), the positive predictive value was 94.71% (161/170), the negative predictive value was 98.14% (370/377), the Jorden index was 0.934.Hysteroscopy diagnosis showed that the endometrial polyps was 54 cases, the pathological diagnosis coincidence rate was 79.63% (43/54); 93 cases of simple hyperplasia, the pathological diagnosis coincidence rate was 90.32% (84/93); 16 cases of atypical hyperplasia, the pathological diagnosis coincidence rate was 87.50% (14/16); 4 cases of differentiated endometrial adenocarcinoma, the pathological diagnosis coincidence rate was 100.00% (4/4); 2 cases of uterine papillary serous carcinoma, the pathological diagnosis coincidence rate was 100.00% (2/2); 1 case of transitional cell carcinoma of endometrium, the pathological diagnosis coincidence rate was 100.00% (1/1). Conclusion Hysteroscopy can visually observe the morphology of cervical canal and uterine cavity, the diagnostic rate of endometrial polyps, simple hyperplasia, atypical hyperplasia and endometrial carcinoma are higher, so it has important clinical value in the diagnosis of abnormal uterine bleeding. Key words: Uterine hemorvhage; Hysteroscopy; Diagnosis

Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy

To study the clinicopathologic features of uterine papillary serous carcinoma (UPSC) and the roles of adjuvant therapy. Sixty-one cases of UPSC with operation done and followed up for a period of 4 to 9 years were enrolled into the study. The histology of slides specimens were reviewed and immunohistochemical study was performed. The follow-up and survival data were analyzed. All of the 61 patients were post-menopausal, with a median age of 68 years. The clinical presentations included abnormal vaginal bleeding, abdominal symptoms and abnormal Pap smears. The median size of the tumors was 7.5 cm (range=1.2 to 14.8 cm). There were 27.9% cases in FIGO stage I (8.2% in stage IA, 14.8% in stage IB and 4.9% in stage IC), 9.8% in stage II, 32.8% in stage III and 29.5% in FIGO stage IV. The histologic features were similar to those of the ovarian counterpart, with tumor cells containing the high-grade nuclei and arranged in complex papillae. Psammoma bodies were identified in 24.6% of the cases. Immunohistochemical study showed that the tumor cells demonstrated diffuse and strong nuclear staining for p53 and Ki-67. They were negative for estrogen receptor and progesterone receptor. Fifteen of the 61 cases (24.6%) showed no evidence of myometrial invasion. However, ten of the 15 cases had extrauterine disease, with peritoneal (6/15) and nodal (9/15) involvement. Tumors with deep myometrial invasion, lymphovascular permeation and nodal metastasis were associated with worse prognosis by univariate analysis. Fifty-six patients received adjuvant therapy. The number of patients receiving adjuvant chemotherapy alone, adjuvant radiotherapy alone and combined adjuvant chemotherapy/radiotherapy were 42, 24 and 10, respectively. The median survivals of the chemotherapy group and non-chemotherapy group (with or without radiotherapy) were 66.4 months and 32.8 months, respectively. UPSC has distinctive clinical and pathologic features. The tumor stage, lymph node status, lymphovascular permeation and depth of myometrial invasion were important prognostic factors. Adjuvant chemotherapy for stage III/IV tumors or recurrent UPSC may have survival benefit.

Polypectomy and endometrial resection in postmenopausal patients

To evaluate the therapeutic efficacy of polypectomy associated with endometrial resection for the treatment of polyps in postmenopausal women. Prospective study (Canadian Task Force classification II-2). Private urban hospital with facilities for endoscopic surgery. Sixty-six women with endometrial polyps. Sixty-four of the 66 patients underwent polypectomy followed by endometrial resection. One patient had hysterectomy because endometrial biopsy showed serous papillary carcinoma. No major complications were associated with the procedure. Histopathology showed hyperplasia in most polyps. One patient had a papillary uterine carcinoma in the polyp that was not detected by preoperative endometrial biopsy. The women were followed with transvaginal sonography for 1 year after surgery. Polypectomy followed by endometrial resection is a very low-risk procedure for postmenopausal patients. There was no recurrence after the first year in women who completed follow-up.

Uterine papillary serous carcinoma with high levels of serum carcinoembryonic antigen. Response to combination chemotherapy

A case of metastatic uterine papillary carcinoma with elevated serum carcinoembryonic antigen (CEA) is reported. The patient presented with ascites and pleural effusions and with a high level of CEA (258 ng/ml) 3 months after primary surgical resection and postoperative irradiation had been performed. Her complete response, although temporary, to two kinds of combination chemotherapy was evaluated using serial estimations of the serum CEA.